CVM - AMEX
CEL-SCI Corporation
$7.17
-6.5%CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
At a Glance
Live SnapshotCEL-SCI Corporation Management Team
Dr. Giovanni Selvaggi M.D.
Acting Chief Medical Officer
Mr. Geert R. Kersten Esq.
Chief Executive & Financial Officer, Treasurer and Director
Compensation
$709,722
Ms. Patricia B. Prichep
Chief Financial & Operations Officer, Compliance Officer & Corporate Secretary
Compensation
$298,225
Dr. Eyal Talor Ph.D.
Chief Scientific Officer
Compensation
$355,643
Mr. John Cipriano
Senior Vice President of Regulatory Affairs
Compensation
$249,593
CEL-SCI Corporation Insider Positioning
During the last 12 months, insiders have purchased $220K worth of CVM shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
32.1K
219.99K
0
0.00
+220K
+$220K
Top Buyers
Kersten Geert R
Director, Officer: Chief Executive Officer
$200K
Watson Robert Eugene
Director
$20K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $220K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
2 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
CVM - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 09, 2025 | March 31, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | March 07, 2024 | March 01, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 10, 2023 | May 23, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 13, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | May 18, 2021 | July 01, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | March 04, 2020 | April 17, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | March 26, 2019 | May 20, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | August 08, 2018 | September 20, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 27, 2017 | June 09, 2017 | 2017 | |
DEF 14A DEF 14A 2016 N/A | June 09, 2016 | July 22, 2016 | 2016 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.